Biosergen
Biosergen publishes interim report for first quarter 2023
REG
Summary of the Interim Report for Q2 2023
| 2023 | 2022 | 2023 | 2022 | 2022 | |
| TSEK | April-June | April-June | Jan-June | Jan-June | Jan-Dec |
| Profit/loss | |||||
| Other income | 2.456 | 1.409 | 7.771 | 2.726 | 5.183 |
| Profit/loss before depreciation (EBITDA | -8.038 | -7.963 | -13.067 | -12.981 | -34.129 |
| Operating profit/loss befor net financials | -8.038 | -7.963 | -13.067 | -12.981 | -34.129 |
| Net financials | 7 | 3 | 9 | 6 | 81 |
| Netprofit/loss for the period | -8.031 | -7.960 | -13.058 | -12.975 | -34.048 |
| Earnings per share (SEK) | -0,19 | -0,28 | -0,31 | -0,46 | -1,09 |
Highlights during Q2 2023
- March 29, Biosergen provides Phase 2 clinical development strategy update.
Highlights after the period
- August 7, Biosergen Announces Abstract Accepted for Presentation at the 11th Congress on Trends in Medical Mycology (TIMM-11)
The Financial report can be found on our website: https://biosergen.net/investors/filings
| Datum | 2023-08-14, kl 08:14 |
| Källa | Cision |
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.
Copy Trading innebär inte investeringsrådgivning. Värdet på dina investeringar kan gå upp eller ner. Du riskerar ditt kapital.